Fatty Liver: Clinical Trials

1012 completed, 369 unknown, 206 recruiting, 112 terminated. 683 Not applicable, 381 Phase 2, 200 Phase 1, 103 Phase 4, 99 Phase 3.

By phase and status

Phase	Trials	Status
Not applicable	683	Completed 369, Unknown 146, Recruiting 67, Active not recruiting 28, Not yet recruiting 23, Terminated 21, Withdrawn 20, Enrolling by invitation 9
Phase 2	381	Completed 236, Terminated 50, Recruiting 29, Unknown 27, Active not recruiting 18, Not yet recruiting 11, Withdrawn 10
Phase 1	200	Completed 137, Recruiting 18, Terminated 16, Unknown 14, Withdrawn 9, Active not recruiting 4, Not yet recruiting 2
Phase 4	103	Completed 57, Unknown 21, Recruiting 8, Terminated 7, Active not recruiting 4, Withdrawn 3, Not yet recruiting 2, Enrolling by invitation 1
Phase 3	99	Completed 45, Unknown 14, Recruiting 12, Terminated 11, Active not recruiting 6, Not yet recruiting 5, Withdrawn 4, Enrolling by invitation 1, Suspended 1
Early Phase 1	19	Completed 12, Active not recruiting 2, Not yet recruiting 2, Unknown 2, Withdrawn 1

Follow Fatty Liver: new trials by email Literature Review of Fatty Liver trials Research Report on Fatty Liver

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction Caloric Restriction, Hyperglycemic clamp - Type2diabetes	Phase 2	Not yet recruiting	Adrian Vella	20	2027-12-15	2026-10-28
Liver Steatosis in Pediatric CD Patients Gluten-free diet - Celiac Disease in Children, Non-Alcoholic Fatty Liver Disease		Recruiting	University of Palermo	91	2027-11-01	2026-05-01
SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease Empagliflozin 10 MG, Placebo Oral Tablet - Non-Alcoholic Fatty Liver Disease, NAFLD	Phase 2	Not yet recruiting	Justin Ryder	40	2027-05-01	2026-01-20
Human Models of Selective Insulin Resistance: Pancreatic Clamp Insulin human, Octreotide Acetate, Glucagon - Insulin Resistance, Hyperinsulinemia	Phase 1	Not yet recruiting	Columbia University	36	2027-01-01	2026-02-06
Diagnosis and Quantification of Hepatic Steatosis Using Near-infrared Spectroscopy Near-infrared spectrometer - Hepatic Transplantation, Steatohepatitis	Not applicable	Not yet recruiting	Assistance Publique Hopitaux De Marseille	90	2027-01-01	2026-09-23
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD) ALN-CIDEB, Placebo - Alcohol-Associated Liver Disease, ALD	Phase 2	Not yet recruiting	Regeneron Pharmaceuticals	120	2026-12-09	2026-11-12
Immunological Signatures of MASLD and MASH in Patients With Type 1 Diabetes Type 1 Diabetes Mellitus (T1D), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)		Not yet recruiting	Assistance Publique - Hôpitaux de Paris	1000	2026-12-01	2026-11-10
RE and Probiotics in MAFLD/NAFLD physical exercise programme, probiotics supplementation, Placebo - NASH, NAFLD	Not applicable	Not yet recruiting	Nicolaus Copernicus University	180	2026-11-10	2026-10-21
DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine ECC0509, Metformin, Caffeine - Steatohepatitis, Nonalcoholic, Osteo Arthritis	Phase 1	Not yet recruiting	Eccogene	40	2026-11-01	2026-10-14
GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease Semaglutide, Weight reduction recommendations (nutritional and exercise) - Adiposity, Fatty Liver	Not applicable	Not yet recruiting	Insel Gruppe AG, University Hospital Bern	64	2026-11-01	2026-08-19
Lifestyle, Dietary Patterns, and Cardiometabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease Among People Living With HIV Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), HIV Infections		Not yet recruiting	Assiut University	250	2026-11-01	2026-10-06
Chinese Overweight/Obesity Cohort: Metabolic & Comorbidity Risks No intervention; observational assessment only - Obesity & Overweight, Diabetes Mellitus, Type 2		Not yet recruiting	Shanxi Bethune Hospital	25974	2026-11-01	2026-10-21
Evaluating the Safety and Efficacy of Roflumilast in the Treatment of Nonalcoholic Fatty Liver Disease Patients Placebo, Roflumilast - NAFLD (Nonalcoholic Fatty Liver Disease)	Phase 2 / Phase 3	Not yet recruiting	Tanta University	60	2026-11-01	2026-10-28
Efficacy of Carnitine Complex in Improving Hepatic Steatosis in Potential Liver Donors GODEX® capsule treatment group - Hepatic Steatosis, Fatty Liver	Not applicable	Not yet recruiting	Samsung Medical Center	40	2026-10-30	2026-11-06
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) ALN-CIDEB, Placebo - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD	Phase 3	Recruiting	Regeneron Pharmaceuticals	1500	2026-10-28	2026-11-05
Evaluating the Safety and Efficacy of Rupatadine in the Treatment of Nonalcoholic Fatty Liver Disease Patients. Placebo, Rupatadin - NAFLD (Nonalcoholic Fatty Liver Disease)	Phase 2 / Phase 3	Not yet recruiting	Tanta University	60	2026-10-25	2026-10-28
Ultrasound Biomarkers for Assessing Eligibility and Response to Resmetirom Therapy Metabolic Dysfunction-steatohepatitis (MASH)		Not yet recruiting	Radnet Management, Inc.	524	2026-10-01	2026-10-06
Wearable Patch Ultrasound Probe for Diagnosis of Liver Stiffness Wearable Patch-Type Ultrasound Probe, Transient Elastography (FibroScan) - Liver Fibrosis, Liver Cirrhosis		Not yet recruiting	Second Affiliated Hospital of Xi'an Jiaotong University	150	2026-10-01	2026-07-21
Metabolic Flux Analysis in Metabolic Dysfunction-Associated Steatotic Liver Disease Bariatric surgery, Stable isotope tracer infusion, MRI/MRE - Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis	Not applicable	Not yet recruiting	Vanderbilt University Medical Center	20	2026-10-01	2026-08-12
Impact of Overt and Subclinical Hypothyroidism on Liver Fibrosis in Patients With MASLD Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease		Not yet recruiting	Assiut University	120	2026-10-01	2026-09-18

Showing 20 of 1938. Sign in to see all of them.

Narrower conditions

Non-alcoholic Fatty Liver Disease (1602)  ·  Obesity (286)  ·  Liver Cirrhosis (171)  ·  Diabetes Mellitus, Type 2 (165)  ·  Metabolic Syndrome (126)  ·  Insulin Resistance (123)  ·  Liver Diseases (110)  ·  Fibrosis (107)  ·  Diabetes Mellitus (94)  ·  Overweight (60)  ·  Motor Activity (47)  ·  Cardiovascular Diseases (44)  ·  Dyslipidemias (43)  ·  Inflammation (40)

Broader conditions

Digestive System Diseases (1919)  ·  Liver Diseases (1828)  ·  Nutritional and Metabolic Diseases (671)  ·  Pathological Conditions, Signs and Symptoms (655)  ·  Metabolic Diseases (472)  ·  Glucose Metabolism Disorders (423)  ·  Signs and Symptoms (376)  ·  Body Weight (356)  ·  Nutrition Disorders (354)  ·  Overnutrition (349)  ·  Pathologic Processes (341)  ·  Overweight (289)  ·  Endocrine System Diseases (283)  ·  Hyperinsulinism (219)

Interventions

Exercise (47)  ·  Metformin (31)  ·  Pioglitazone (27)  ·  Diet (25)  ·  Vitamin E (25)  ·  semaglutide (23)  ·  empagliflozin (22)  ·  Bariatric Surgery (21)  ·  Diet, Mediterranean (19)  ·  Blood Specimen Collection (15)  ·  Diet Therapy (14)  ·  Diet, Fat-Restricted (14)  ·  Magnetic Resonance Imaging (13)  ·  Probiotics (13)  ·  Ultrasonography (13)

Sponsors

Assiut University (29)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (22)  ·  Cairo University (19)  ·  Massachusetts General Hospital (17)  ·  AstraZeneca (16)  ·  Gilead Sciences (16)  ·  Novo Nordisk A/S (15)  ·  Pfizer (15)  ·  Tanta University (15)  ·  University of California, San Diego (15)  ·  Columbia University (14)  ·  University of Aarhus (14)  ·  Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis (13)  ·  Chinese University of Hong Kong (13)  ·  Maastricht University Medical Center (13)

Countries

United States (630)  ·  China (171)  ·  United Kingdom (141)  ·  France (126)  ·  Italy (117)  ·  Canada (106)  ·  Germany (97)  ·  Spain (93)  ·  Egypt (81)  ·  South Korea (75)  ·  Israel (73)  ·  Puerto Rico (71)  ·  Belgium (62)  ·  Australia (60)  ·  Denmark (59)

Top investigators

Stephen Harrison, MD (7)  ·  Joshua R Cook, MD, PhD (6)  ·  Raika Jamali, M.D. (5)  ·  Ali Ismail, lecturer (4)  ·  Ali MA Ismail, lecturer (4)  ·  Claude B Sirlin, MD (4)

Results publications

PMID 36318027, PMID 40434633, PMID 33307033, PMID 36750244, PMID 37786277, PMID 40568349, PMID 42014131, PMID 18820647, PMID 26707365, PMID 30639779, PMID 32027858, PMID 33454241, PMID 39326675, PMID 17081293, PMID 18086506, PMID 19827166, PMID 20427778, PMID 21520200, PMID 21618575, PMID 22338037, PMID 22431131, PMID 23396737, PMID 24042449, PMID 24187469, PMID 24360972, PMID 24740208, PMID 24743428, PMID 25040896, PMID 26511519, PMID 26602219, PMID 28039099, PMID 28346567, PMID 28545937, PMID 29895557, PMID 29990488, PMID 30221912, PMID 30779990, PMID 31235380, PMID 31271665, PMID 31301251, PMID 32044314, PMID 32147362, PMID 32278004, PMID 32360804, PMID 32674604, PMID 33210751, PMID 33293204, PMID 33344496, PMID 33584535, PMID 33657443

NIH funding

2019 (13), 2016 (12), 2017 (9), 2018 (9), 2023 (7), U01DK061730 (6), U01DK061728 (5), R01HD040787 (4), U01DK061732 (4), U01DK061737 (4), 2025 (3), K12DK133995 (3), P30DK063608 (3), U01DK061713 (3), U01DK061718 (3)